Diseases of protein aggregation and the hunt for potential pharmacological agents

Biotechnology Journal

Volumn 3, Issue 2, 2008, Pages 165-192

  Wang, Steven S S ^a   Wu, Josephine W ^b   Yamamoto, Shuichi ^c   Liu, Hwai Shen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Cataract; Protein aggregation

Indexed keywords

BIOCHEMICAL RESEARCH; PATHOGENESIS; PROTEIN AGGREGATION;

AGGLOMERATION; BIOCHEMICAL ENGINEERING; DISEASES; DRUG PRODUCTS; ENGINEERING RESEARCH; EPIDEMIOLOGY;

PROTEINS;

ACETYLCHOLINE; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA CAROTENE; CARNOSINE; COMPACTIN; CONJUGATED ESTROGEN; CRYSTALLIN; CURCUMIN; DONEPEZIL; FILIPIN; GALANTAMINE; GINKGO BILOBA EXTRACT; HUPERZINE A; METHYL BETA CYCLODEXTRIN; MEVINOLIN; NICOTINIC ACID; NORDIHYDROGUAIARETIC ACID; PRESENILIN 1; PRESENILIN 2; REACTIVE OXYGEN METABOLITE; RIBOFLAVIN; RIFAMPICIN; RIVASTIGMINE; SIALIDASE; TANNIN; UNINDEXED DRUG; PROTEIN;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BIOCHEMISTRY; CATARACT; CATARACT EXTRACTION; CHROMOSOME 19; DEUTERIUM HYDROGEN EXCHANGE; DRUG EFFICACY; DRUG PENETRATION; DRUG RESEARCH; ENZYME INHIBITION; EPIDEMIOLOGICAL DATA; GENE MUTATION; HUMAN; HYDROPHOBICITY; HYPOTHESIS; MEMBRANE PERMEABILITY; MICELLIZATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN HYDROLYSIS; PROTEIN STRUCTURE; REVIEW; CHEMISTRY; DRUG EFFECT; METABOLISM; PROTEIN DENATURATION;

ALZHEIMER DISEASE; CATARACT; HUMANS; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEINS;

EID: 41049092281     PISSN: 18606768     EISSN: None     Source Type: Journal    
DOI: 10.1002/biot.200700065     Document Type: Review

References (367)

1. Markossian, K. A., Kurganov, B. I., Protein folding, misfolding, and aggregation. Formation of inclusion bodies and aggresomes. Biochemistry (Mosc) 2004, 69, 971-84.
2. Young, J. C., Agashe, V. R., Siegers, K., Hartl, F. U., Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell. Biol. 2004, 5, 781-91.
3. Stefani, M., Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim. Biophys. Acta 2004, 1739, 5-25.
4. Pastor, M. T., Esteras-Chopo, A., Lopez de la Paz, M., Design of model systems for amyloid formation: lessons for prediction and inhibition. Curr. Opin. Struct. Biol. 2005, 15, 57-63.
5. Mesquida, P., Blanco, E. M., McKendry, R. A., Patterning amyloid peptide fibrils by AFM charge writing. Langmuir 2006, 22, 9089-9091.
6. MacPhee, C. E., Dobson, C. M., Formation of mixed fibrils demonstrates the generic nature and potential utility of amyloid nanostructures. J. Am. Chem. Soc. 2000, 122, 12707-12713.
7. Clark, E. D., Protein refolding for industrial processes. Curr. Opin. Biotechnol. 2001, 12, 202-207.
8. Singh, S. M., Panda, A. K., Solubilization and refolding of bacterial inclusion body proteins. J. Biosci. Bioeng. 2005, 99, 303-310.
9. Bondos, S. E., Methods for measuring protein aggregation. Curr. Anal. Chem. 2006, 2, 157-170.
10. Wang, W., Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 2005, 289, 1-30.
11. Jungbauer, A., Kaar, W., Current status of technical protein refolding. J. Biotechnol. 2007, 128, 587-596.
12. Jungbauer, A., Kaar, W., Schlegl, R., Folding and refolding of proteins in chromatographic beds. Cur. Opin. Biotechnol. 2004, 15, 487-494.
13. Wang, S. S. S., Chang, C. K., Liu, H. S., A study on the refolding of lysozyme using fed-batch and step-addition strategies. J. Chinese Inst. Chem. Engineers 2004, 35, 389-398.
14. Wang, S. S. S., Chang, C. K., Liu, H. S., Step change of mobile phase flow rates to enhance protein folding in size exclusion chromatography. Biochem. Eng.g J. 2006, 29, 2-11.
15. Wang, S. S. S., Chang, C. K., Peng, M. J., Liu, H. S., Effect of glutathione redox system on lysozyme refolding in size exclusion chromatography. Food Bioprod.s Process. 2006, 84, 18-27.
16. Liu, H. S., Chang, C. K., Chaperon solvent plug to enhance protein refolding in size exclusion chromatography. Enzyme Microb. Technol. 2003, 33, 424-429.
17. Uversky, V. N., Fink, A. L., Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim. Biophys. Acta 2004, 1698, 131-153.
18. Dobson, C. M., Principles of protein folding, misfolding and aggregation. Semin. Cell. Dev. Biol. 2004, 15, 3-16.
19. Ross, C. A., Poirier, M. A., Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10 Suppl, S10-17.
20. Wang, S. S.S., Good, T. A., An overview of Alzheimer's disease. J. Chinese Inst. Chem. Engineers 2005, 36, 533-559.
21. Dobson, C. M., Protein folding and its links with human disease. From Protein Folding to New Enzymes 2001, 1-26.
22. Ohnishi, S., Takano, K., Amyloid fibrils from the viewpoint of protein folding. Cell. Mol. Life Sci. 2004, 61, 511-524.
23. Oberg, K., Chrunyk, B. A., Wetzel, R., Fink, A. L., Nativelike secondary structure in interleukin-1 beta inclusion bodies by attenuated total reflectance FTIR. Biochemistry 1994, 33, 2628-2634.
24. Soto, C., Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 2003, 4, 49-60.
25. Stefani, M., Dobson, C. M., Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 2003, 81, 678-699.
26. Wang, S. S. S., Chen, Y. T., Chen, P. H., Liu, K. N., A kinetic study on the aggregation behavior of beta-amyloid peptides in different initial solvent environments. Biochem. Eng. J. 2006, 29, 129-138.
27. Kodaka, M., Requirements for generating sigmoidal time-course aggregation in nucleation-dependent polymerization model. Biophys. Chem. 2004, 107, 243-253.
28. Akkermans, C., Venema, P., Rogers, S. S., van der Goot, A. J. et al., Shear pulses nucleate fibril aggregation. Food Biophysics 2006, 1, 144-150.
29. Giri, K., Bhattacharyya, N. P., Basak, S., pH-dependent self-assembly of polyalanine peptides. Biophys. J. 2007, 92, 293-302.
30. Soto, C., Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches. J. Mol. Med. 1999, 77, 412-418.
31. Ji, S. R., Wu, Y., Sui, S. F., Study of the correlation of secondary structure of beta-amyloid peptide (Aβ40) with the hydrophobic exposure under different conditions. Gen. Physiol. Biophys. 2002, 21, 415-427.
32. Rahbar, S., Figarola, J. L., Novel inhibitors of advanced glycation endproducts. Arch. Biochem. Biophys. 2003, 419, 63-79.
33. Seidler, N. W., Yeargans, G. S., Morgan, T. G., Carnosine disaggregates glycated alpha-crystallin: an in vitro study. Arch. Biochem. Biophys. 2004, 427, 110-115.
34. Kikuchi, S., Shinpo, K., Takeuchi, M., Yamagishi, S. et al., Glycation - a sweet tempter for neuronal death. Brain Res. Rev. 2003, 41, 306-323.
35. Nilsson, M. R., Techniques to study amyloid fibril formation in vitro. Methods 2004, 34, 151-160.
36. Lai, Z., Colon, W., Kelly, J. W., The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996, 35, 6470-6482.
37. Ferrao-Gonzales, A. D., Souto, S. O., Silva, J. L., Foguel, D., The preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic state. Proc. Natl. Acad. Sci. USA 2000, 97, 6445-6450.
38. Sluzky, V., Klibanov, A. M., Langer, R., Mechanism of insulin aggregation and stabilization in agitated aqueous-solutions. Biotechnol. Bioeng. 1992, 40, 895-903.
39. Wang, S. S. S., Chen, P. H., Hung, Y. T., Effects of p-benzoquinone and melatonin on amyloid fibrillogenesis of hen egg-white lysozyme. J. Mol. Catalysis B-Enzymatic 2006, 43, 49-57.
40. Fandrich, M., Forge, V., Buder, K., Kittler, M. et al., Myoglobin forms amyloid fibrils by association of unfolded polypeptide segments. Proc. Natl. Acad. Sci. USA 2003, 100, 15463-15468.
41. Schuster, D., Rajendran, A., Hui, S. W., Nicotera, T. et al., Protective effect of colostrinin on neuroblastoma cell survival is due to reduced aggregation of beta-amyloid. Neuropeptides 2005, 39, 419-426.
42. De Felice, F. G., Vieira, M. N. N., Meirelles, M. N. L., Morozova-Roche, L. A. et al., Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure. FASEB J. 2004, 18, 1099-1101.
43. Wang, S. S., Good, T. A., Rymer, D. L., The influence of phospholipid membranes on bovine calcitonin peptide's secondary structure and induced neurotoxic effects. Int. J. Biochem. Cell. Biol. 2005, 37, 1656-1669.
44. Nussbaum, R. L., Ellis, C. E., Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 2003, 348, 1356-1364.
45. Bullock, R., Future directions in the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs 2004, 13, 303-314.
46. Cummings, J. L., Alzheimer's disease. N. Engl. J. Med. 2004, 351, 56-67.
47. Bird, T. D., Genetic factors in Alzheimer's disease. N. Engl. J. Med. 2005, 352, 862-864.
48. Terry, R. D., Katzman, R., Senile dementia of the Alzheimer type. Ann. Neurol. 1983, 14, 497-506.
49. Saunders, A. M., Gene identification in Alzheimer's disease. Pharmacogenomics 2001, 2, 239-249.
50. Zekanowski, C., Religa, D., Graff, C., Filipek, S., Kuznicki, J., Genetic aspects of Alzheimer's disease. Acta Neurobiol. Exp. (Wars) 2004, 64, 19-31.
51. Selkoe, D. J., Biochemistry of altered brain proteins in Alzheimer's disease. Annu. Rev. Neurosci. 1989, 12, 463-490.
52. Cummings, B. J., Pike, C. J., Shankle, R., Cotman, C. W., Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol. Aging 1996, 17, 921-933.
53. Tandon, A., Fraser, P., The presenilins. Genome Biol. 2002, 3, reviews3014.
54. Holcomb, L., Gordon, M. N., McGowan, E., Yu, X. et al., Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998, 4, 97-100.
55. Selkoe, D. J., Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 1996, 271, 18295-18298.
56. Kowalska, A., Pruchnik-Wolinska, D., Florczak, J., Modestowicz, R. et al., Genetic study of familial cases of Alzheimer's disease. Acta Biochim. Pol. 2004, 51, 245-252.
57. Nagele, R. G., Wegiel, J., Venkataraman, V., Imaki, H., Wang, K. C., Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol. Aging 2004, 25, 663-674.
58. Bornemann, K. D., Staufenbiel, M., Transgenic mouse models of Alzheimer's disease. Ann. NY Acad. Sci. 2000, 908, 260-266.
59. Sivaprakasam, K., Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation. Curr. Med. Chem. 2006, 13, 2179-2188.
60. Kar, S., Slowikowski, S. P., Westaway, D., Mount, H. T., Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J. Psychiatry Neurosci. 2004, 29, 427-441.
61. Haass, C., Hung, A. Y., Schlossmacher, M. G., Oltersdorf, T. et al., Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. Ann. NY Acad. Sci. 1993, 695, 109-116.
62. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M. et al., The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325, 733-736.
63. Dyrks, T., Weidemann, A., Multhaup, G., Salbaum, J. M. et al., Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease. EMBO J. 1988, 7, 949-957.
64. Selkoe, D. J., Podlisny, M. B., Joachim, C. L., Vickers, E. A. et al., Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc. Natl. Acad. Sci. USA 1988, 85, 7341-7345.
65. Kitaguchi, N., Takahashi, Y., Tokushima, Y., Shiojiri, S., Ito, H., Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity. Nature 1988, 331, 530-532.
66. Naidu, A., Quon, D., Cordell, B., Beta-amyloid peptide produced in vitro is degraded by proteinases released by cultured cells. J. Biol. Chem. 1995, 270, 1369-1374.
67. Buxbaum, J. D., Oishi, M., Chen, H. I., Pinkas-Kramarski, R. et al., Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA 1992, 89, 10075-10078.
68. Caporaso, G. L., Gandy, S. E., Buxbaum, J. D., Ramabhadran, T. V., Greengard, P., Protein phosphorylation regulates secretion of Alzheimer beta/A4 amyloid precursor protein. Proc. Natl. Acad. Sci. USA 1992, 89, 3055-3059.
69. Gabuzda, D., Busciglio, J., Yankner, B. A., Inhibition of beta-amyloid production by activation of protein kinase C. J. Neurochem 1993, 61, 2326-2329.
70. Nitsch, R. M., Farber, S. A., Growdon, J. H., Wurtman, R. J., Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc. Natl. Acad. Sci. USA 1993, 90, 5191-5193.
71. Martins, R. N., Robinson, P. J., Chleboun, J. O., Beyreuther, K., Masters, C. L., The molecular pathology of amyloid deposition in Alzheimer's disease. Mol. Neurobiol. 1991, 5, 389-398.
72. Ishiura, S., Proteolytic cleavage of the Alzheimer's disease amyloid A4 precursor protein. J. Neurochem. 1991, 56, 363-369.
73. Small, D. H., Mok, S. S., Bornstein, J. C., Alzheimer's disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 2001, 2, 595-598.
74. Michaelis, M. L., Arisar, S., Chen, Y., Reiff, E. R. et al., [beta]-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J. Pharmacol. Exp. Ther. 2005, 312, 659-668.
75. Ciccotosto, G. D., Tew, D., Curtain, C. C., Smith, D. et al., Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J. Biol. Chem. 2004, 279, 42528-42534.
76. Wang, S. S., Rymer, D. L., Good, T. A., Reduction in cholesterol and sialic Acid content protects cells from the toxic effects of beta -amyloid peptides. J. Biol. Chem. 2001, 276, 42027-42034.
77. Plant, L. D., Boyle, J. P., Smith, I. F., Peers, C., Pearson, H. A., The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J. Neurosci. 2003, 23, 5531-5535.
78. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C. et al.. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 1998, 95, 6448-6453.
79. Hartley, D. M., Walsh, D. M., Ye, C. P., Diehl, T. et al., Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 1999, 19, 8876-8884.
80. Ward, R. V., Jennings, K. H., Jepras, R., Neville, W. et al., Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. Biochem. J. 2000, 348, 137-144.
81. De Felice, F. G., Vieira, M. N., Saraiva, L. M., Figueroa-Villar, J. D. et al., Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J. 2004, 18, 1366-1372.
82. Klein, W. L., Stine, W. B., Jr., Teplow, D. B., Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging 2004, 25, 569-580.
83. Serpell, L. C., Alzheimer's amyloid fibrils: structure and assembly. Biochim. Biophys. Acta 2000, 1502, 16-30.
84. Lynn, D. G., Meredith, S. C., Review: model peptides and the physicochemical approach to beta-amyloids. J. Struct. Biol. 2000, 130, 153-173.
85. Festy, F., Lins, L., Peranzi, G., Octave, J. N. et al.. Is aggregation of beta-amyloid peptides a mis-functioning of a current interaction process? Biochim. Biophys. Acta 2001, 1546, 356-364.
86. Demeester, N., Baier, G., Enzinger, C., Goethals, M. et al., Apoptosis induced in neuronal cells by C-terminal amyloid beta- fragments is correlated with their aggregation properties in phospholipid membranes. Mol. Membr. Biol. 2000, 17, 219-228.
87. Demeester, N., Mertens, C., Caster, H., Goethals, M. et al., Comparison of the aggregation properties, secondary structure and apop-totic effects of wild-type. Flemish and Dutch N-terminally truncated amyloid beta peptides. Eur. J. Neurosci. 2001, 13, 2015-2024.
88. Jacchieri, S. G., Study of alpha-helix to beta-strand to beta-sheet transitions in amyloid: the role of segregated hydrophobic beta-strands. Biophys. Chem. 1998, 74, 23-34.
89. Nordstedt, C., Naslund, J., Tjernberg, L. O., Karlstrom, A. R. et al., The Alzheimer A beta peptide develops protease resistance in association with its polymerization into fibrils. J. Biol. Chem. 1994, 269, 30773-30776.
90. Simmons, L. K., May, P. C., Tomaselli, K. J., Rydel, R. E. et al., Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol. Pharmacol. 1994, 45, 373-379.
91. Fezoui, Y., Teplow, D. B., Kinetic studies of amyloid beta-protein fibril assembly. Differential effects of alpha-helix stabilization. J. Biol. Chem. 2002, 277, 36948-36954.
92. Stine, W. B., Jr., Dahlgren, K. N., Krafft, G. A., LaDu, M. J., In vitro characterization of conditions for amyloid-beta peptide oligomerization fibrillogenesis. J. Biol. Chem. 2003, 278, 11612-11622.
93. Kawooya, J. K., Emmons, T. L., Gonzalez-DeWhitt, P A., Camp, M. C., D'Andrea, S. C., Electrophoretic mobility of Alzheimer's amyloid-beta peptides in urea-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal. Biochem. 2003, 323, 103-113.
94. Coles, M., Bicknell, W., Watson, A. A., Fairlie, D. P., Craik, D. J., Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry 1998, 37, 11064-11077.
95. Gursky, O., Aleshkov, S., Temperature-dependent beta-sheet formation in beta-amyloid Abeta(1-40) peptide in water: uncoupling beta-structure folding from aggregation. Biochim. Biophys. Acta 2000, 1476, 93-102.
96. Szabo, Z., Klement, E., Jost, K., Zarandi, M. et al. An FT-IR study of the beta-amyloid conformation: standardization of aggregation grade. Biochem. Biophys. Res. Commun. 1999, 265, 297-300.
97. Garzon-Rodriguez, W., Sepulveda-Becerra, M., Milton, S., Glabe, C. G., Soluble amyloid Abeta-(1-40) exists as a stable dimer at low concentrations. J. Biol. Chem. 1997, 272, 21037-21044.
98. Shen, C. L., Murphy, R. M., Solvent effects on self-assembly of beta-amyloid peptide. Biophys. J. 1995, 69, 640-651.
99. Jarrett, J. T., Berger, E. P., Lansbury P. T., Jr., The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32, 4693-4697.
100. Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M., Teplow, D. B., Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 1997, 272, 22364-22372.
101. Frears, E. R., Stephens, D. J., Walters, C. E., Davies, H., Austen, B. M., The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 1999, 10, 1699-1705.
102. Mansfield, S. L., Jayawickrama, D. A., Timmons, J. S., Larive, C. K., Measurement of peptide aggregation with pulsed-field gradient nuclear magnetic resonance spectroscopy. Biochim. Biophys. Acta 1998, 1382, 257-265.
103. Pallitto, M. M., Ghanta, J., Heinzelman, P., Kiessling, L. L., Murphy, R. M., Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. Biochemistry 1999, 38, 3570-3578.
104. Tjernberg, L. O., Naslund, J., Lindqvist, F., Johansson, J. et al., Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 1996, 271, 8545-8548.
105. Esler, W. P., Stimson, E. R., Ghilardi, J. R., Vinters, H. V. et al., In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics. Biochemistry 1996, 35, 749-757.
106. Hilbich, C., Kisters-Woike, B., Reed, J., Masters, C. L., Beyreuther, K., Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. J. Mol. Biol. 1991, 218, 149-163.
107. Soto, C., Castano, E. M., Frangione, B., Inestrosa, N. C., The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J. Biol. Chem. 1995, 270, 3063-3067.
108. Wood, S. J., Wetzel, R., Martin, J. D., Hurle, M. R., Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. Biochemistry 1995, 34, 724-730.
109. Tjernberg, L. O., Callaway, D. J., Tjernberg, A., Hahne, S. et al., A molecular model of Alzheimer amyloid beta-peptide fibril formation. J. Biol. Chem. 1999, 274, 12619-12625.
110. He, W., Barrow, C. J., The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry 1999, 38, 10871-10877.
111. Wang, S. S., Tobler, S. A., Good, T. A., Fernandez, E. J., Hydrogen exchange-mass spectrometry analysis of beta-amyloid peptide structure. Biochemistry 2003, 42, 9507-9514.
112. Whittemore, N. A., Mishra, R., Kheterpal, I., Williams, A. D. et al., Hydrogen-deuterium (H/D) exchange mapping of Abeta 1-40 amyloid fibril secondary structure using nuclear magnetic resonance spectroscopy. Biochemistry 2005, 44, 4434-4441.
113. Kheterpal, I., Chen, M., Cook, K. D., Wetzel, R., Structural differences in Abeta amyloid protofibrils and fibrils mapped by hydrogen exchange - mass spectrometry with on-line proteolytic fragmentation. J. Mol. Biol. 2006, 361, 785-795.
114. Kheterpal, I., Cook, K. D., Wetzel, R., Hydrogen/deuterium exchange mass spectrometry analysis of protein aggregates. Methods Enzymol. 2006, 413, 140-166.
115. Kheterpal, I., Lashuel, H. A., Hartley, D. M., Walz, T. et al., Abeta protofibrils possess a stable core structure resistant to hydrogen exchange. Biochemistry 2003, 42, 14092-14098.
116. Kheterpal, I., Zhou, S., Cook, K. D., Wetzel, R., Abeta amyloid fibrils possess a core structure highly resistant to hydrogen exchange. Proc. Natl. Acad. Sci. USA 2000, 97, 13597-13601.
117. Tomski, S. J., Murphy, R. M., Kinetics of aggregation of synthetic beta-amyloid peptide. Arch. Biochem. Biophys. 1992, 294, 630-638.
118. Lomakin, A., Chung, D. S., Benedek, G. B., Kirschner, D. A., Teplow, D. B., On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc. Natl. Acad. Sci. USA 1996, 93, 1125-1129.
119. Jarrett, J. T., Lansbury, P. T., Jr., Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry 1992, 31, 12345-12352.
120. Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J. et al. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J. Biol. Chem. 1992, 267, 546-554.
121. Naiki, H., Nakakuki, K., First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. Lab. Invest. 1996, 74, 374-383.
122. Snyder, S. W., Ladror, U. S., Wade, W. S., Wang, G. T. et al., Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 1994, 67, 1216-1228.
123. Soreghan, B., Kosmoski, J., Glabe, C., Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. J. Biol. Chem. 1994, 269, 28551-28554.
124. Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E. et al., Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1994, 91, 4766-4770.
125. Miyata, T., Inagi, R., Iida, Y., Sato, M. et al., Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J. Clin. Invest. 1994, 93, 521-528.
126. Busciglio, J., Yeh, J., Yankner, B. A., beta-Amyloid neurotoxicity in human cortical culture is not mediated by excitotoxins. J. Neurochem. 1993, 61, 1565-1568.
127. Howlett, D. R., Jennings, K. H., Lee, D. C., Clark, M. S. et al., Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 1995, 4, 23-32.
128. Seilheimer, B., Bohrmann, B., Bondolfi, L., Muller, F. et al., The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. J. Struct. Biol. 1997, 119, 59-71.
129. Hoshi, M., Sato, M., Matsumoto, S., Noguchi, A. et al., Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc. Natl. Acad. Sci. USA 2003, 100, 6370-6375.
130. Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y. et al., Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 1999, 274, 25945-25952.
131. Wang, S. S., Becerra-Arteaga, A., Good, T. A., Development of a novel diffusion-based method to estimate the size of the aggregated Abeta species responsible for neurotoxicity Biotechnol. Bioeng. 2002, 80, 50-59.
132. Butterfield, D. A., Lauderback, C. M., Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 2002, 32, 1050-1060.
133. Pratico, D., Alzheimer's disease and oxygen radicals: new insights. Biochem. Pharmacol. 2002, 63, 563-567.
134. Pereira, C., Santos, M. S., Oliveira, C., Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants. Neurobiol. Di.s 1999, 6, 209-219.
135. Davis, J. B., Oxidative mechanisms in beta-amyloid cytotoxicity. Neurodegeneration 1996, 5, 441-444.
136. Matsuoka, Y., Picciano, M., La Francois, J., Duff, K., Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience 2001, 104, 609-613.
137. Pratico, D., Clark, C. M., Lion, F., Rokach, J. et al., Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 2002, 59, 972-976.
138. Yatin, S. M., Aksenov, M., Butterfield, D. A., The antioxidant vitamin E modulates amyloid beta-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. Neurochem. Res. 1999, 24, 427-435.
139. Yatin, S. M., Varadarajan, S., Link, C. D., Butterfield, D. A., In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol. Aging 1999, 20, 325-30; discussion 339-342.
140. 2+ homeostasis and cell death. J. Neurosci. 1995, 15, 6239-6249.
141. Kawahara, M., Kuroda, Y., Intracellular calcium changes in neuronal cells induced by Alzheimer's beta-amyloid protein are blocked by estradiol and cholesterol. Cell. Mol. Neurobiol. 2001, 21, 1-13.
142. Mark, R. J., Blanc, E. M., Mattson, M. P., Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease. Mol. Neurobiol. 1996, 12, 211-224.
143. Butterfield, D. A., Yatin, S. M., Varadarajan, S., Koppal, T., Amyloid beta-peptide-associated free radical oxidative stress, neurotoxicity, and Alzheimer's disease, Amyloid, Prions, and Other Protein Aggregates, 1999, pp. 746-768, Academic Press, San Diego, CA, USA.
144. Varadarajan, S., Yatin, S., Aksenova, M., Butterfield, D. A., Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity [In Process Citation]. J. Struct. Biol. 2000, 130, 184-208.
145. Terzi, E., Holzemann, G., Seelig, J., Interaction of Alzheimer beta-amyloid peptide(1-40) with lipid membranes. Biochemistry 1997, 36, 14845-14852.
146. Wood, W. G., Eckert, G. P., Igbavboa, U., Muller, W. E., Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochim. Biophys. Acta-Biomembranes 2003, 1610, 281-290.
147. Verdier, Y., Zarandi, M., Penke, B., Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J. Pept. Sci. 2004, 10, 229-248.
148. Buchet, R., Pikula, S., Alzheimer's disease: its origin at the membrane, evidence and questions. Acta Biochim. Pol. 2000, 47, 725-733.
149. Hartmann, H., Eckert, A., Muller, W. E., Apolipoprotein E and cholesterol affect neuronal calcium signalling: the possible relationship to beta-amyloid neurotoxicity. Biochem. Biophys. Res. Commun. 1994, 200, 1185-1192.
150. Muller, W. E., Koch, S., Eckert, A., Hartmann, H., Scheuer, K., Beta-Amyloid peptide decreases membrane fluidity. Brain Res. 1995, 674, 133-136.
151. Muller, W. E., Eckert, G. P., Scheuer, K., Cairns, N. J. et al., Effects of beta-amyloid peptides on the fluidity of membranes from frontal and parietal lobes of human brain. High potencies of A beta 1- 42 and A beta 1-43. Amyloid 1998, 5, 10-15.
152. Kremer, J. J., Pallitto, M. M., Sklansky, D. J., Murphy R. M., Correlation of beta-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry 2000, 39, 10309-10318.
153. Muller, W. E., Kirsch, C., Eckert, G. P., Membrane-disordering effects of beta-amyloid peptides. Biochem. Soc. Trans. 2001, 29, 617-623.
154. Mason, R. P., Jacob, R. F., Walter, M. F., Mason, P. E. et al., Distribution and fluidizing action of soluble and aggregated amyloid beta-peptide in rat synaptic plasma membranes. J. Biol. Chem. 1999, 274, 18801-18807.
155. Avdulov, N. A., Chochina, S. V., Igbavboa, U., O'Hare, E. O. et al., Amyloid beta-peptides increase annular and bulk fluidity and induce lipid peroxidation in brain synaptic plasma membranes. J. Neurochem. 1997, 68, 2086-2091.
156. Chochina, S. V., Avdulov, N. A., Igbavboa, U., Cleary, J. P. et al., Amyloid beta-peptide1-40 increases neuronal membrane fluidity: role of cholesterol and brain region. J. Lipid Res. 2001, 42, 1292-1297.
157. Terzi, E., Holzemann, G., Seelig, J., Self-association of beta-amyloid peptide (1-40) in solution and binding to lipid membranes. J. Mol. Bio. 1995, 252, 633-642.
158. Seelig, J., Lehrmann, R., Terzi, E., Domain formation induced by lipid-ion and lipid-peptide interactions. Mol. Membr. Biol. 1995, 12, 51-57.
159. Hertel, C., Terzi, E., Hauser, N., Jakob-Rotne, R., Seelig, J., Kemp, J. A., Inhibition of the electrostatic interaction between beta-amyloid peptide and membranes prevents beta-amyloid-induced toxicity. Proc. Natl. Acad. Sci. USA 1997, 94, 9412-9416.
160. Butterfield, D. A., Hensley, K., Harris, M., Mattson, M., Carney, J., beta-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem. Biophys. Res. Commun. 1994, 200, 710-715.
161. Eliezer, D., Amyloid ion channels: a porous argument or a thin excuse? J. Gen. Physiol. 2006, 128, 631-633.
162. Quist, A., Doudevski, I., Lin, H., Azimova, R. et al.. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. USA 2005, 102, 10427-10432.
163. Kagan, B. L., Azimov, R., Azimova, R., Amyloid peptide channels. J. Membr. Biol. 2004, 202, 1-10.
164. Pollard, H. B., Arispe, N., Rojas, E., Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Cell. Mol. Neurobiol. 1995, 15, 513-526.
165. 2+ interaction with Alzheimer amyloid beta protein calcium channels. Proc. Natl. Acad. Sci. USA 1996, 93, 1710-1715.
166. Kagan, B. L., Azimov, R., Azimova, R. K., Hirakura, Y., Amyloid channel properities suggest a common mechanism of action. Biophys. J. 2002, 82, 17A-17A.
167. Kagan, B. L., Hirakura, Y., Azimov, R., Azimova, R., Lin, M. C., The channel hypothesis of Alzheimer's disease: current status. Peptides 2002, 23, 1311-1315.
168. Hirakura, Y., Lin, M. C., Kagan, B. L., Alzheimer amyloid abeta1-42 channels: effects of solvent, pH, and Congo Red. J. Neurosci. Res. 1999, 57, 458-466.
169. Vaudry, D., Cottet-Rousselle, C., Basille, M., Falluel-Morel, A. et al., Pituitary adenylate cyclase-activating polypeptide inhibits caspase-3 activity but does not protect cerebellar granule neurons against beta-amyloid (25-35)-induced apoptosis. Regul. Pept. 2004, 123, 43-49.
170. Jonsson, K. O., Hedin, H. L., Fowler, C. J., Investigation into the rapid effects of 17 beta-estradiol and neuroactive steroids upon beta-amyloid(25-35)+induced activation of phosphoinositide-specific phospholipase C in human platelets. Methods Find. Exp. Clin. Pharmacol. 2000, 22, 615-620.
171. 2+- and cholinergic receptor-mediated phosphoinositide degradation by alteration of membrane and cytosolic phospholipase C in brain cortex. Neurochem. Res. 2000, 25, 189-196.
172. Zhang, C., Qiu, H. E., Krafft, G. A., Klein, W. L., Protein kinase C and F-actin are essential for stimulation of neuronal FAX tyrosine phosphorylation by G-proteins and amyloid beta protein. FEBS Lett. 1996, 386, 185-188.
173. Soomets, U., Mahlapuu, R., Tehranian, R., Jarvet, J. et al., Regulation of GTPase and adenylate cyclase activity by amyloid beta- peptide and its fragments in rat brain tissue. Brain Res. 1999, 850, 179-188.
174. Brouillet, E., Trembleau, A., Galanaud, D., Volovitch, M. et al., The amyloid precursor protein interacts with Go heterotrimeric protein within a cell compartment specialized in signal transduction. J. Neurosci. 1999, 19, 1717-1727.
175. Rymer, D. L., Good, T. A., The role of G protein activation in the toxicity of amyloidogenic Abeta- (1-40), Abeta-(25-35), and bovine calcitonin. J. Biol. Chem. 2001, 276, 2523-2530.
176. Molnar, Z., Kovacs, P., Laczko, I., Soos, K. et al.. Enhanced G-protein activation by a mixture of Abeta(25-35), Abeta(1-40/42) and zinc. J. Neurochem. 2004, 89, 1215-1223.
177. Wang, S. S., Kazantzi, V., Good, T. A., A kinetic analysis of the mechanism of beta-amyloid induced G protein activation. J. Theor. Biol. 2003, 221, 269-278.
178. Avdulov, N. A., Chochina, S. V., Igbavboa, U., Warden, C. S. et al., Lipid binding to sterol carrier protein-2 is inhibited by ethanol. Biochim. Biophys. Acta 1999, 1437, 37-45.
179. Matsuzaki, K., Horikiri, C., Interactions of amyloid beta-peptide (1-40) with ganglioside-containing membranes. Biochemistry 1999, 38, 4137-4142.
180. Ariga, T., Yu, R. K., GM1 inhibits amyloid beta-protein-induced cytokine release. Neurochem. Res. 1999, 24, 219-226.
181. Wang, S. S., Good, T. A., Rymer, D. L., The influence of phospholipid membranes on bovine calcitonin secondary structure and amyloid formation. Protein Sci. 2005, 14, 1419-1428.
182. Mizuno, T., Nakata, M., Naiki, H., Michikawa, M. et al., Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J. Biol. Chem. 1999, 274, 15110-15114.
183. Del Mar Martinez-Senac, M., Villalain, J., Gomez-Fernandez, J. C., Structure of the Alzheimer beta-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles. Eur. J. Biochem. 1999, 265, 744-753.
184. Simons, M., Keller, P., De Strooper, B., Beyreuther, K. et al., Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 1998, 95, 6460-6464.
185. Yeagle, P. L., Modulation of membrane function by cholesterol. Biochimie 1991, 73, 1303-1310.
186. Mitchell, D. C., Straume, M., Miller, J. L., Litman, B. J., Modulation of metarhodopsin formation by cholesterol-induced ordering of bilayer lipids. Biochemistry 1990, 29, 9143-9149.
187. Bretscher, M. S., Munro, S., Cholesterol and the Golgi apparatus. Science 1993, 261, 1280-1281.
188. Klein, I., Moore, L., Pastan, I., Effect of liposomes containing cholesterol on adenylate cyclase activity of cultured mammalian fibroblasts. Biochim. Biophys. Acta 1978, 506, 42-53.
189. Klein, U., Gimpl, G., Fahrenholz, F., Alteration of the myometrial plasma membrane cholesterol content with beta-cyclodextrin modulates the binding affinity of the oxytocin receptor. Biochemistry 1995, 34, 13784-13793.
190. Sinha, A. K., Shattil, S. J., Colman, R. W., Cyclic AMP metabolism in cholesterol-rich platelets. J. Biol. Chem. 1977, 252, 3310-3314.
191. Schroeder, F., Jefferson, J. R., Kier, A. B., Knittel, J. et al., Membrane cholesterol dynamics: cholesterol domains and kinetic pools. Proc. Soc. Exp. Biol. Med. 1991, 196, 235-252.
192. Mayeux, R., Launer, L., Yaffe, K., Genetic and environmental risk factors for Alzheimer's disease. Am. J. Epidemiol. 2002, 155, 101.
193. Sambamurti, K., Granholm, A. C., Kindy, M. S., Bhat, N. R. et al., Cholesterol and Alzheimer's disease: Clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr. Drug Targets 2004, 5, 517-528.
194. Graham, D. I., Gentleman, S. M., Nicoll, J. A., Royston, M. C. et al., Is there a genetic basis for the deposition of beta-amyloid after fatal head injury? Cell. Mol. Neurobiol. 1999, 19, 19-30.
195. Sadowski, M., Pankiewicz, J., Scholtzova, H., Ripellino, J. A. et al., A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am. J. Pathol. 2004, 165, 937-948.
196. Jarvik, G. P., Wijsman, E. M., Kukull, W. A., Schellenberg, G. D. et al., Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995, 45, 1092-1096.
197. Notkola, I. L., Sulkava, R., Pekkanen, J., Erkinjuntti, T. et al., Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998, 17, 14-20.
198. Czech, C., Forstl, H., Hentschel, F., Monning, U. et al., Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: prevalence, plasma cholesterol levels and cerebrovascular change. Eur. Arch. Psychiatry Clin. Neurosci. 1994, 243, 291-292.
199. Evans, R. M., Emsley, C. L., Gao, S., Sahota, A. et al., Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000, 54, 240-242.
200. Racchi, M., Baetta, R., Salvietti, N., Ianna, P. et al., Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem. J. 1997, 322, 893-898.
201. Galbete, J. L., Martin, T. R., Peressini, E., Modena, P. et al., Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem. J. 2000, 348, 307-313.
202. Shie, F. S., LeBoeuf, R. C., Leverenz, J. B., Jin, L. W., Effects of cholesterol feeding on histopathologic hallmarks of Alzheimer's disease in β-amyloid precursor protein (APP) transgenic mice. Soc. Neurosci. 1999, 25, 1859.
203. Fishman, C. E., White, S.L., DeLong, C. A., Cummins, D. J. et al., High fat diet potentiates β-amyloid deposition in the APP V717F transgenic mouse model of Alzheimer's disease. Soc. Neurosci. 1999, 25, 1859.
204. Li, L., Zeigler, S., Lindsey, R. J., Fukuchi, K., Effects of an atherogenic diet on amyloidosis in transgenic mice over-expressing the C-terminal portion of β-amyloid precursor protein. Soc. Neurosci. 1999, 25, 1859.
205. Refolo, L. M., Malester, B., LaFrancois, J., Bryant-Thomas, T. et al., Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 2000, 7, 321-331.
206. Refolo, L. M., Pappolla, M. A., LaFrancois, J., Malester, B. et al., A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2001, 8, 890-899.
207. Fassbender, K., Simons, M., Bergmann, C., Stroick, M. et al., Simvastatin strongly reduces levels of Alzheimer's disease beta - amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2001, 98, 5856-5861.
208. Golde, T. E., Eckman, C. B., Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. Drug Discov. Today 2001, 6, 1049-1055.
209. Wiegandt, H., Kanda, S., Inoue, K., Utsumi, K., Nojima, S., Studies on the cell association of exogenous glycolipids. Adv. Exp. Med. Biol. 1982, 152, 343-352.
210. Tettamanti, G., Riboni, L., Gangliosides and modulation of the function of neural cells. Adv. Lipid. Res. 1993, 25, 235-267.
211. Hansson, H. A., Holmgren, J., Svennerholm, L., Ultrastructural localization of cell membrane GM1 ganglioside by cholera toxin. Proc. Natl. Acad. Sci. USA 1977, 74, 3782-3786.
212. Cutler, R. G., Kelly, J., Storie, K., Pedersen, W. A. et al.. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2004, 101, 2070-2075.
213. Yanagisawa, K., Odaka, A., Suzuki, N., Ihara, Y., GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease [see comments]. Nat. Med. 1995, 1, 1062-1066.
214. Yanagisawa, K., Asami-Odaka, A., Suzuki, N., Ihara, Y., Fractionation of amyloid beta-protein (A beta) in Alzheimer's disease and Down's syndrome brains. Presence of membrane-bound A beta. Ann. NY Acad. Sci. 1996, 786, 184-194.
215. Yanagisawa, K., Ihara, Y., GM1 ganglioside-bound amyloid beta-protein in Alzheimer's disease brain. Neurobiol. Aging 1998, 19, S65-67.
216. Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., Matsuzaki, K., Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: Importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 2002, 41, 7385-7390.
217. Tashima, Y., Oe, R., Lee, S., Sugihara, G. et al., The effect of cholesterol and monosialoganglioside (GM1) on the release and aggregation of amyloid beta-peptide from liposomes prepared from brain membrane-like lipids. J. Biol. Chem. 2004, 279, 17587-17595.
218. Yamamoto, N., Igbabvoa, U., Shimada, Y., Ohno-Iwashita, Y. et al., Accelerated Abeta aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett. 2004, 569, 135-139.
219. Wakabayashi, M., Okada, T., Kozutsumi, Y., Matsuzaki, K., GM1 ganglioside-mediated accumulation of amyloid beta-protein on cell membranes. Biochem. Biophys. Res. Commun. 2005, 328, 1019-1023.
220. Klafki, H. W., Staufenbiel, M., Kornhuber, J., Wiltfang, J., Therapeutic approaches to Alzheimer's disease. Brain 2006, 129, 2840-2855.
221. Hodges, J. R., Alzheimer's centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspects. Brain 2006, 129, 2811-2822.
222. Estrada, L. D., Soto, C., Disrupting beta-amyloid aggregation for Alzheimer disease treatment. Curr. Top. Med. Chem. 2007, 7, 115-126.
223. Blennow, K., de Leon, M. J., Zetterberg, H., Alzheimer's disease. Lancet 2006, 368, 387-403.
224. Porat, Y., Abramowitz, A., Gazit, E., Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 2006, 67, 27-37.
225. Lorenzo, A., Yankner, B. A., Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 1994, 91, 12243-12247.
226. Klunk, W. E., Debnath, M. L., Koros, A. M., Pettegrew, J. W., Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci. 1998, 63, 1807-1814.
227. Howlett, D. R., Perry, A. E., Godfrey, F., Swatton, J. E. et al., Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. Biochem. J. 1999, 340, 283-289.
228. Tomiyama, T., Kaneko, H., Kataoka, K., Asano, S., Endo, N., Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem. J. 1997, 322, 859-865.
229. Tomiyama, T., Shoji, A., Kataoka, K., Suwa, Y. et al., Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J. Biol. Chem. 1996, 271, 6839-6844.
230. Wang, S. S., Chen, Y. T., Chou, S. W., Inhibition of amyloid fibril formation of beta-amyloid peptides via the amphiphilic surfactants. Biochim. Biophys. Acta 2005, 1741, 307-313.
231. Wood, S. J., MacKenzie, L., Maleeff, B., Hurle, M. R., Wetzel, R., Selective inhibition of Abeta fibril formation. J. Biol. Chem. 1996, 271, 4086-4092.
232. Ono, K., Yoshiike, Y., Takashima, A., Hasegawa, K. et al., Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem. 2003, 87, 172-181.
233. Defelice, F. G., Ferreira, S. T., Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer's disease. An. Acad. Bras. Cienc. 2002, 74, 265-284.
234. Thomas, T., Nadackal, T. G., Thomas, K., Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 2001, 12, 3263-3267.
235. Fung, J., Darabie, A. A., McLaurin, J., Contribution of simple saccharides to the stabilization of amyloid structure. Biochem. Biophys. Res. Commun. 2005, 328, 1067-1072.
236. Liu, R., Barkhordarian, H., Emadi, S., Park, C. B., Sierks, M. R., Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol. Dis. 2005, 20, 74-81.
237. Soto, C., Sigurdsson, E. M., Morelli, L., Kumar, R. A. et al., Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 1998, 4, 822-826.
238. Hetenyi, C., Szabo, Z., Klement, E., Datki, Z. et al., Pentapeptide amides interfere with the aggregation of beta-amyloid peptide of Alzheimer's disease. Biochem. Biophys. Res. Commun. 2002, 292, 931-936.
239. Ghanta, J., Shen, C. L., Kiessling, L. L., Murphy, R. M., A strategy for designing inhibitors of beta-amyloid toxicity. J. Biol. Chem. 1996, 271, 29525-29528.
240. Pallitto, M. M., Ghanta, J., Heinzelman, P., Kiessling, L. L., Murphy, R. M., Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. Biochemistry 1999, 38, 3570-3578.
241. Fulop, L., Zarandi, M., Datki, Z., Soos, K., Penke, B., Beta-amyloid-derived pentapeptide RIIGLa inhibits Abeta(1-42) aggregation and toxicity. Biochem. Biophys. Res. Commun. 2004, 324, 64-69.
242. Datki, Z., Papp, R., Zadori, D., Soos, K. et al., In vitro model of neurotoxicity of Abeta 1-42 and neuroprotection by a pentapeptide: irreversible events during the first hour. Neurobiol. Dis.2004, 17, 507-515.
243. Lee, S., Carson, K., Rice-Ficht, A., Good, T., Hsp20, a novel {alpha}-crystallin, prevents A{beta} fibril formation and toxicity. Protein Sci. 2005, 14, 593-601.
244. Santhoshkumar, P., Sharma, K. K., Inhibition of amyloid fibrillogenesis and toxicity by a peptide chaperone. Mol. Cell. Biochem. 2004, 267, 147-155.
245. Adessi, C., Soto, C., Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 2002, 9, 963-978.
246. Sjogren, M., Mielke, M., Gustafson, D., Zandi, P., Skoog, I., Cholesterol and Alzheimer's disease - is there a relation? Mech. Ageing Dev. 2006, 127, 138-147.
247. Rojo, L., Sjoberg, M. K., Hernandez, P., Zambrano, C., Maccioni, R. B., Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer's disease. J. Biomed. Biotechnol. 2006, 2006, 73976.
248. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., Siegel, G., Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000, 57, 1439-1443.
249. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., Drachman, D. A., Statins and the risk of dementia. Lancet 2000, 356, 1627-1631.
250. Resnikoff, S., Pascolini, D., Etya'ale, D., Kocur, I. et al., Global data on visual impairment in the year 2002. Bull. World Health Organ. 2004, 82, 844-851.
251. McCarty, C. A., Keeffe, J. E., Taylor, H. R., The need for cataract surgery: projections based on lens opacity, visual acuity, and personal concern. Br. J. Ophthalmol. 1999, 83, 62-65.
252. West, S. K., Duncan, D. D., Munoz, B., Rubin, G. S. et al., Sunlight exposure and risk of lens opacities in a population-based study: the Salisbury Eye Evaluation project. JAMA 1998, 280, 714-718.
253. Brian, G., Taylor, H., Cataract blindness - challenges for the 21st century. Bul. World Health Organ. 2001, 79, 249-56.
254. Riaz, Y., Mehta, J. S., Wormald, R., Evans, J. R. et al.. Surgical interventions for age-related cataract. Cochrane Database Syst. Rev. 2006, CD001323.
255. Sommer, A., Global access to eye care. Arch. Ophthalmol. 2007, 125, 399-400.
256. Oyster, C. W., The Human Eye, Sinauer Associates Incorporated 1999.
257. Fleschner, C. R., Connexin 46 and connexin 50 in selenite cataract. Ophthalmic Res. 2006, 38, 24-28.
258. Delamere, N. A., Manning, R. E., Jr., Liu, L., Moseley, A. E., Dean, W. L., Na,K-ATPase polypeptide upregulation responses in lens epithelium. Invest. Ophthalmol. Vis. Sci. 1998, 39, 763-768.
259. Pau, H., Cortical and subcapsular cataracts: significance of physical forces. Ophthalmologica 2006, 220, 1-5.
260. Andley, U. P., Crystallins in the eye: Function and pathology Prog. Retin. Eye Res. 2007, 26, 78-98.
261. Bloemendal, H., de Jong, W., Jaenicke, R., Lubsen, N. H. et al., Ageing and vision: structure, stability and function of lens crystallins. Prog. Biophys. Mol. Biol. 2004, 86, 407-485.
262. Ponce, A., Sorensen, C., Takemoto, L., Role of short-range protein interactions in lens opacifications. Mol. Vis. 2006, 12, 879-884.
263. Sun, Y., MacRae, T. H., The small heat shock proteins and their role in human disease. FEBS J. 2005, 272, 2613-2627.
264. Sgarbossa, A., Youssef, T., Lenci, F., Photosensitized structural modifications of the lens protein alpha-crystallin: do all modifications impair chaperone-like activity? Photochem. Photobiol. 2003, 77, 567-571.
265. Farnsworth, P., Singh, K., Structure function relationship among alpha-crystallin related small heat shock proteins. Exp. Eye Res. 2004, 79, 787-794.
266. Sreelakshmi, Y., Sharma, K. K., The interaction between alphaA- and alphaB-crystallin is sequence-specific.Mol. Vis. 2006, 12, 581-587.
267. Srikanthan, D., Bateman, O. A., Purkiss, A.G., Slingsby, C., Sulfur in human crystallins. Exp. Eye Res. 2004, 79, 823-831.
268. Regini, J. W., Grossmann, J. G., Burgio, M. R., Malik, N. S. et al., Structural changes in alpha-crystallin and whole eye lens during heating, observed by low-angle X-ray diffraction. J. Mol. Biol. 2004, 336, 1185-1194.
269. Kumar, M. S., Kapoor, M., Sinha, S., Reddy, G. B., Insights into hydrophobicity and the chaperone-like function of alphaA- and alphaB-crystallins: an isothermal titration calorimetric study. J. Biol. Chem. 2005, 280, 21726-21730.
270. Liao, J. H., Lee, J. S., Chiou, S. H., Distinct roles of alphaA-and alphaB-crystallins under thermal and UV stresses. Biochem. Biophys. Res. Commun. 2002, 295, 854-861.
271. Liang, J. J., Sun, T. X., Akhtar, N. J., Heat-induced conformational change of human lens recombinant alphaA- and alphaB-crystallins. Mol. Vis. 2000, 6, 10-14.
272. Abgar, S., Backmann, J., Aerts, T., Vanhoudt, J., Clauwaert, J., The structural differences between bovine lens alphaA-and alphaB-crystallin. Eur. J. Biochem. 2000, 267, 5916-5925.
273. Shroff, N. P., Cherian-Shaw, M., Bera, S., Abraham, E. C., Mutation of R116C results in highly oligomerized alpha A-crystallin with modified structure and defective chaperone-like function. Biochemistry 2000, 39, 1420-1426.
274. Treweek, T. M., Rekas, A., Lindner, R. A., Walker, M. J. et al., R120G alphaB-crystallin promotes the unfolding of reduced alpha-lactalbumin and is inherently unstable. FEBS J. 2005, 272, 711-724.
275. Liu, Y., Zhang, X., Luo, L., Wu, M. et al., A novel alphaB-crystallin mutation associated with autosomal dominant congenital lamellar cataract. Invest. Ophthalmol. Vis. Sci. 2006, 47, 1069-1075.
276. Singh, D., Raman, B., Ramakrishna, T., Rao Ch, M., The cataract-causing mutation G98R in human alphaA-crystallin leads to folding defects and loss of chaperone activity. Mol. Vis. 2006, 12, 1372-1379.
277. Goishi, K., Shimizu, A., Najarro, G., Watanabe, S. et al., AlphaA-crystallin expression prevents gamma-crystallin insolubility and cataract formation in the zebrafish cloche mutant lens. Development 2006, 133, 2585-2593.
278. Brady, J. P., Garland, D. L., Green, D. E., Tamm, E. R. et al., AlphaB-crystallin in lens development and muscle integrity: a gene knockout approach. Invest. Ophthalmol. Vis. Sci. 2001, 42, 2924-2934.
279. Boyle, D. L., Takemoto, L., Brady, J. P., Wawrousek, E. F., Morphological characterization of the Alpha A- and Alpha B-crystallin double knockout mouse lens. BMC Ophthalmol. 2003, 3, 3.
280. Horwitz, J., Alpha-crystallin. Exp. Eye Res. 2003, 76, 145-153.
281. Kumar, M. S., Reddy, P. Y., Kumar, P. A., Surolia, I., Reddy, G. B., Effect of dicarbonyl-induced browning on alpha-crystallin chaperone-like activity: physiological significance and caveats of in vitro aggregation assays. Biochem. J. 2004, 379, 273-282.
282. Sergeev, Y. V., Hejtmancik, J. F., Wingfield, P. T., Energetics of domain-domain interactions and entropy driven association of beta-crystallins. Biochemistry 2004, 43, 415-424.
283. MacDonald, J. T., Purkiss, A. G., Smith, M. A., Evans, P. et al., Unfolding crystallins: the destabilizing role of a beta-hairpin cysteine in betaB2-crystallin by simulation and experiment. Protein Sci. 2005, 14, 1282-1292.
284. Liu, B. F., Liang, J. J., Domain interaction sites of human lens betaB2-crystallin. J. Biol. Chem. 2006, 281, 2624-2630.
285. Pande, A., Pande, J., Asherie, N., Lomakin, A. et al.. Molecular basis of a progressive juvenile-onset hereditary cataract. Proc. Natl. Acad. Sci. USA 2000, 97, 1993-1998.
286. Kosinski-Collins, M. S., Flaugh, S. L., King, J. Probing folding and fluorescence quenching in human gammaD crystallin Greek key domains using triple tryptophan mutant proteins. Protein Sci. 2004, 13, 2223-2235.
287. Flaugh, S. L., Kosinski-Collins, M. S., King, J. Interdomain side-chain interactions in human gammaD crystallin influencing folding and stability. Protein Sci. 2005, 14, 2030-2043.
288. Van Montfort, R. L., Bateman, O. A., Lubsen, N. H., Slingsby C., Crystal structure of truncated human betaB1-crystallin. Protein Sci. 2003, 12, 2606-2612.
289. Bateman, O. A., Sarra, R., van Genesen, S. T., Kappe, G. et al., The stability of human acidic beta-crystallin oligomers and hetero-oligomers. Exp. Eye Res. 2003, 77, 409-422.
290. Hejtmancik, J. F., Wingfield, P. T., Sergeev, Y. V., Beta-crystallin association. Exp. Eye. Res. 2004, 79, 377-383.
291. Marin-Vinader, L., Onnekink, C., van Genesen, S. T., Slingsby, C., Lubsen, N. H., In vivo heteromer formation. Expression of soluble betaA4-crystallin requires coexpression of a heteromeric partner. FEBS J. 2006, 273, 3172-3182.
292. Mackay, D. S., Boskovska, O. B., Knopf, H. L., Lampi, K. J., Shiels, A., A nonsense mutation in CRYBB1 associated with autosomal dominant cataract linked to human chromosome 22q. Am. J. Hum. Genet. 2002, 71, 1216-1221.
293. Ferrini, W., Schorderet, D. F., Othenin-Girard, P., Uffer, S. et al., CRYBA3/A1 gene mutation associated with suture-sparing autosomal dominant congenital nuclear cataract: a novel phenotype. Invest. Ophthalmol. Vis. Sci. 2004, 45, 1436-1441.
294. Liu, B. F., Liang, J. J., Interaction and biophysical properties of human lens Q155* betaB2-crystallin mutant. Mol. Vis. 2005, 11, 321-327.
295. Pande, A., Pande, J., Asherie, N., Lomakin, A. et al., Crystal cataracts: human genetic cataract caused by protein crystallization. Proc. Natl. Acad. Sci. USA 2001, 98, 6116-6120.
296. Basak, A., Bateman, O., Slingsby, C., Pande, A. et al., High-resolution X-ray crystal structures of human gammaD crystallin (1.25 A) and the R58H mutant (1.15 A) associated with aculeiform cataract. J. Mol. Biol. 2003, 328, 1137-1147.
297. Evans, P., Wyatt, K., Wistow, G. J., Bateman, O. A. et al., The P23T cataract mutation causes loss of solubility of folded gammaD-crystallin. J. Mol. Biol. 2004, 343, 435-444.
298. Pigaga, V., Quinlan, R. A., Lenticular chaperones suppress the aggregation of the cataract-causing mutant T5P gamma C-crystallin. Exp. Cell. Res. 2006, 312, 51-62.
299. Weinreb, O., van Rijk, A. F., Dovrat, A., Bloemendal, H., In vitro filament-like formation upon interaction between lens alpha-crystallin and betaL-crystallin promoted by stress. Invest. Ophthalmol. Vis. Sci. 2000, 41, 3893-3897.
300. Liang, J. J., Interactions and chaperone function of alphaA-crystallin with T5P gammaC-crystallin mutant. Protein Sci. 2004, 13, 2476-2482.
301. Sathish, H. A., Koteiche, H. A., McHaourab, H. S., Binding of destabilized betaB2-crystallin mutants to alpha-crystallin: the role of a folding intermediate. J. Biol. Chem. 2004, 279, 16425-16432.
302. Udupa, P. E., Sharma, K. K., Effect of oxidized betaB3-crystallin peptide (152-166) on thermal aggregation of bovine lens gamma-crystallins: identification of peptide interacting sites. Exp. Eye Res. 2005, 80, 185-196.
303. Wang, X., Garcia, C. M., Shui, Y. B., Beebe, D. C., Expression and regulation of alpha-, beta-, and gamma-crystallins in mammalian lens epithelial cells. Invest. Ophthalmol. Vis. Sci. 2004, 45, 3608-3619.
304. Xi, J. H., Bai, F., McGaha, R., Andley, U. P., Alpha-crystallin expression affects microtubule assembly and prevents their aggregation. FASEB J. 2006, 20, 846-857.
305. Andley, U. P., Song, Z., Wawrousek, E. F., Brady, J. P. et al., Lens epithelial cells derived from alphaB-crystallin knockout mice demonstrate hyperproliferation and genomic instability. FASEB J. 2001, 15, 221-229.
306. Morozov, V., Wawrousek, E. F., Caspase-dependent secondary lens fiber cell disintegration in alphaA-/alphaB-crystallin double-knockout mice. Development 2006, 133, 813-821.
307. Yan, H., Lou, M. F., Fernando, M. R., Harding, J. J., Thioredoxin, thioredoxin reductase, and alpha-crystallin revive inactivated glyceraldehyde 3-phosphate dehydrogenase in human aged and cataract lens extracts. Mol. Vis. 2006, 12, 1153-1159.
308. Alge, C. S., Priglinger, S. G., Neubauer, A. S., Kampik, A. et al., Retinal pigment epithelium is protected against apoptosis by alphaB-crystallin. Invest. Ophthalmol. Vis. Sci. 2002, 43, 3575-3582.
309. Kamradt, M. C., Lu, M., Werner, M. E., Kwan, T. et al., The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J. Biol. Chem. 2005, 280, 11059-11066.
310. Yoshimura, N., Kikuchi, T., Kuroiwa, S., Gaun, S., Differential temporal and spatial expression of immediate early genes in retinal neurons after ischemia-reperfusion injury Invest. Ophthalmol. Vis. Sci. 2003, 44, 2211-2220.
311. Vazquez-Chona, F., Song, B. K., Geisert, E. E., Jr., Temporal changes in gene expression after injury in the rat retina. Invest. Ophthalmol. Vis. Sci. 2004, 45, 2737-2746.
312. Zhang, C., Gehlbach, P., Gongora, C., Cano, M. et al., A potential role for beta- and gamma-crystalins in the vascular remodeling of the eye. Dev. Dyn. 2005, 234, 36-47.
313. Maeda, A., Ohguro, H., Maeda, T., Nakagawa, T., Kuroki, Y., Low expression of alphaA-crystallins and rhodopsin kinase of photoreceptors in retinal dystrophy rat. Invest. Ophthalmol. Vis. Sci. 1999, 40, 2788-2794.
314. Crabb, J. W., Miyagi, M., Gu, X., Shadrach, K. et al.. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc. Natl. Acad. Sci. USA 2002, 99, 14682-14687.
315. Umeda, S., Ayyagari, R., Allikmets, R., Suzuki, M. T. et al., Early-onset macular degeneration with drusen in a cynomolgus monkey ( Macaca fascicularis) pedigree: exclusion of 13 candidate genes and loci. Invest. Ophthalmol. Vis. Sci. 2005, 46, 683-691.
316. Nakata, K., Crabb, J. W., Hollyfield, J. G., Crystallin distribution in Bruch's membrane-choroid complex from AMD and age-matched donor eyes. Exp. Eye Res. 2005, 80, 821-626.
317. Furuyoshi, N., Furuyoshi, M., May, C. A., Hayreh, S. S et al., Vascular and glial changes in the retrolaminar optic nerve in glaucomatous monkey eyes. Ophthalmologica 2000, 214, 24-32.
318. Maloyan, A., Sanbe, A., Osinska, H., Westfall, M et al., Mitochondrial dysfunction and apoptosis underlie the pathogenic process in alpha-B-crystallin desmin-related cardiomyopathy. Circulation 2005, 112, 3451-3461.
319. den Engelsman, J., Gerrits, D., de Jong, W. W., Robbins, J. et al., Nuclear import of {alpha}B-crystallin is phosphorylation-dependent and hampered by hyperphosphorylation of the myopathy-related mutant R120G. J. Biol. Chem. 2005, 280, 37139-37148.
320. Laudanski, K., Wyczechowska, D., The distinctive role of small heat shock proteins in oncogenesis. Arch. Immunol. Ther. Exp. (Warsz) 2006, 54, 103-111.
321. Muchowski, P. J., Wacker, J. L., Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 2005, 6, 11-22.
322. Sinclair, C., Mirakhur, M., Kirk, J., Farrell, M., McQuaid, S., Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathol. Appl. Neurobiol. 2005, 31, 292-303.
323. Wilhelmus, M. M., Otte-Holler, I., Wesseling, P., de Waal, R. M. et al., Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. Neuropathol. Appl. Neurobiol. 2006, 32, 119-130.
324. Delcourt, C., Dupuy, A. M., Carriere, I., Lacroux, A., Cristol, J. P., Albumin and transthyretin as risk factors for cataract: the POLA study. Arch. Ophthalmol. 2005, 123, 225-232.
325. Ajamian, P. C., Traumatic cataract. Optom. Clin. 1993, 3, 49-56.
326. Ferrufino-Ponce, Z. K., Henderson, B.A., Radiotherapy and cataract formation. Semin. Ophthalmol. 2006, 21, 171-180.
327. Yanoff, M., Duker, J. S., The Lens, Ophthalmology, Mosby, New York 1999.
328. Mitchell, P., Cumming, R. G., Attebo, K., Panchapakesan, J., Prevalence of cataract in Australia: the Blue Mountains eye study. Ophthalmology 1997, 104, 581-588.
329. Klein, B. E., Klein, R., Linton, K. L., Prevalence of age-related lens opacities in a population. The Beaver Dam Eye Study. Ophthalmology 1992, 99, 546-552.
330. Brown, N. P., Bron, A. J., Lens Disorders, Butterworth-Heinemann, 1996, Oxford, UK.
331. Truscott, R. J., Age-related nuclear cataract-oxidation is the key. Exp. Eye Res. 2005, 80, 709-725.
332. Lampi, K. J., Shih, M., Ueda, Y., Shearer, T. R., David, L. L., Lens proteomics: analysis of rat crystallin sequences and two-dimensional electrophoresis map. Invest. Ophthalmol. Vis. Sci. 2002, 43, 216-224.
333. Cobb, B. A., Petrash, J. M., alpha-Crystallin chaperone-like activity and membrane binding in age-related cataracts. Biochemistry 2002, 41, 483-490.
334. Grami, V., Marrero, Y., Huang, L., Tang, D. et al., alpha-Crystallin binding in vitro to lipids from clear human lenses. Exp. Eye Res. 2005, 81, 138-146.
335. Fan, J., Fariss, R. N., Purkiss, A. G., Slingsby, C. et al., Specific interaction between lens MIP/Aquaporin-0 and two members of the gamma-crystallin family. Mol. Vis. 2005, 11, 76-87.
336. Kodama, T., Takemoto, L., Characterization of disulfide-linked crystallins associated with human cataractous lens membranes. Invest. Ophthalmol. Vis. Sci. 1988, 29, 145-149.
337. Nixon, R. A., The calpains in aging and aging-related diseases. Ageing Re. Rev. 2003, 2, 407-418.
338. Biswas, S., Harris, F., Dennison, S., Singh, J. P., Phoenix, D., Calpains: enzymes of vision? Med. Sci. Monit. 2005, 11, RA301-310.
339. Miyazawa, T., Kubo, E., Takamura, Y., Akagi, Y., Up-regulation of P-glycoprotein expression by osmotic stress in rat sugar cataract. Exp. Eye Res. 2007, 84, 246-253.
340. Srivastava, S. K., Ramana, K. V., Bhatnagar, A., Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev. 2005, 26, 380-392.
341. Scalbert, P., Birlouez-Aragon, I., Relationship between lens protein glycation and membrane structure in human cataract. Exp. Eye Res. 1993, 56, 335-340.
342. Clark, J. I., Matsushima, H., David, L. L., Clark, J. M., Lens cytoskeleton and transparency: a model. Eye 1999, 13, 417-424.
343. Moffat, B. A., Landman, K. A., Truscott, R. J., Sweeney M. H., Pope, J. M., Age-related changes in the kinetics of water transport in normal human lenses. Exp. Eye Res. 1999, 69, 663-669.
344. Harding, J. J., Can drugs or micronutrients prevent cataract? Drugs Aging 2001, 18, 473-486.
345. Williams, D. L., Oxidation, antioxidants and cataract formation: a literature review. Vet. Ophthalmol. 2006, 9, 292-298.
346. Wang, S., Li, D., Ito, Y., Nabekura, T. et al., Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats. Curr. Eye Res. 2004, 29, 51-58.
347. Varma, S. D., Hegde, K. R., Kovtun, S., Oxidative damage to lens in culture: reversibility by pyruvate and ethyl pyruvate. Ophthalmologica 2006, 220, 52-57.
348. Zigler, J. S., Jr., Qin, C., Kamiya, T., Krishna, M. C. et al., Tempol-H inhibits opacification of lenses in organ culture. Free Radic. Biol. Med. 2003, 35, 1194-1202.
349. Shvachko, A. G., Formaziuk, V. E., Sergienko, V.I., [Chemiluminescence decrease of singlet oxygen in NaClO+H2O2 reaction in the presence of different anti-cataract drugs]. Biull. Eksp. Biol. Med. 1991, 112, 42-44.
350. Biswas, N. R., Mongre, P. K., Das, G. K., Sen, S. et al., Animal study on the effects of catalin on aftercataract and posterior capsule opacification. Ophthalmic Res. 1999, 31, 140-142.
351. Ciuffi, M., Neri, S., Franchi-Micheli, S., Failli, P. et al., Protective effect of pirenoxine and U74389F on induced lipid peroxidation in mammalian lenses. An in vitro, ex vivo and in vivo study. Exp. Eye Res. 1999, 68, 347-359.
352. Kociecki, J., Zalecki, K., Wasiewicz-Rager, J., Pecold, K., [Evaluation of effectiveness of Catalin eyedrops in patients with presenile and senile cataract]. Klin. Oczna 2004, 106, 778-782.
353. Sekimoto, M., Imanaka, Y., Kitano, N., Ishizaki, T., Takahashi, O., Why are physicians not persuaded by scientific evidence? A grounded theory interview study. BMC Health Serv. Res. 2006, 6, 92.
354. AREDS-Group, A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss. Arch. Ophthalmol. AREDS Report no 9 2001, 119, 1439-1452.
355. Chylack, L. T., Jr., Brown, N. P., Bron, A., Hurst, M. et al., The Roche European American Cataract Trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract. Ophthalmic Epidemiol. 2002, 9, 49-80.
356. Waagbo, R., Hamre, K., Bjerkas, E., Berge, R. et al., Cataract formation in Atlantic salmon, Salmo salar L., smolt relative to dietary pro- and antioxidants and lipid level. J. Fish Dis. 2003, 26, 213-229.
357. Jacques, P. F., Taylor, A., Moeller, S., Hankinson, S. E. et al., Long-term nutrient intake and 5-year change in nuclear lens opacities. Arch. Ophthalmol. 2005, 123, 517-526.
358. Ohta, Y., Yamasaki, T., Niwa, T., Majima, Y., Ishiguro, I., Preventive effect of topical vitamin E-containing liposome instillation on the progression of galactose cataract. Comparison between 5-week- and 12-week-old rats fed a 25% galactose diet. Exp. Eye Res. 1999, 68, 747-755.
359. Chung, Y. S., Choi, Y. H., Lee, S. J., Choi, S. A. et al., Water extract of Aralia elata prevents cataractogenesis in vitro and in vivo. J. Ethnopharmacol. 2005, 101, 49-54.
360. Kador, P. F., Betts, D., Wyman, M., Blessing, K., Randazzo, J., Effects of topical administration of an aldose reductase inhibitor on cataract formation in dogs fed a diet high in galactose. Am. J. Vet. Res. 2006, 67, 1783-1787.
361. Sun, Y., MacRae, T. H., Small heat shock proteins: molecular structure and chaperone function. Cell. Mol. Life Sci. 2005, 62, 2460-2476.
362. Yan, H., Harding, J. J., Carnosine inhibits modifications and decreased molecular chaperone activity of lens alpha-crystallin induced by ribose and fructose 6-phosphate. Mol. Vis. 2006, 12, 205-214.
363. Yan, H., Harding, J. J., Carnosine protects against the inactivation of
364. Yan, H., Harding, J. J., Protective effect of carnosine against inactivation of enzymes induced by glycation and a steroid: relevance to cataract. Am. J. Ophthalmol. 2005, 139, S55.
365. Babizhayev, M. A., Deyev, A. I., Yermakova, V. N., Semiletov, Y. A. et al., Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R D 2002, 3, 87-103.
366. Babizhayev, M. A., Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuvenation Res. 2004, 7, 186-198.
367. Williams, D. L., Munday, P., The effect of a topical antioxidant formulation including N-acetyl carnosine on canine cataract: a preliminary study. Vet. Ophthalmol. 2006, 9, 311-316.